|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
<i>Nrf2-lncRNA</i> levels correlated with the recurrence-free postsurgery survival rate of patients with hepatocellular carcinoma.
|
30897343 |
2019 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Hepatocellular carcinomas divert glucose metabolism to the anabolic shunt by activating transcription factor NRF2.
|
24203292 |
2014 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Nrf2 was up-regulated in HCC, and expression of Nrf2 was correlated with tumor differentiation, metastasis, and tumor size.
|
26194347 |
2015 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Nrf2-mediated anti-oxidant effects contribute to suppression of non-alcoholic steatohepatitis-associated hepatocellular carcinoma in murine model.
|
30279623 |
2018 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Nrf2 and NF-κB are the key transcription factors that regulate oxidative stress and inflammation, therefore we assessed whether TX modulate these pathways and its downstream proteins in HuH-7 hepatocarcinoma cells.
|
30389603 |
2019 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
All of our data confirmed that oxidative stress-mediated mitochondrial apoptosis (especially the Nrf-2/HO-1 pathway) is responsible for 5h2c-induced HCC damage.
|
30055129 |
2018 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
An inhibitor of phosphorylated p62-dependent Nrf2 activation suppresses the proliferation and anticancer agent tolerance of HCC.
|
27345495 |
2016 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
ATO reduced Nrf2 and antioxidant enzyme superoxide dismutase-2 (SOD2) expression in human hepatocarcinoma HepG2 cells.
|
31423616 |
2019 |
|
Liver carcinoma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Clinical implication of Keap1 and phosphorylated Nrf2 expression in hepatocellular carcinoma.
|
27650414 |
2016 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Collectively, our results indicate the presence of a novel NRF2 SUMOylation-mediated signaling process that maintains HCC tumorigenesis in normal conditions and in response to metabolic stress.
|
31546024 |
2019 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Collectively, the present investigation suggest that the NRAL/miR-340-5p/Nrf2 axis mediates cisplatin resistance in HCC, which may provide novel targets for overcoming cisplatin resistance in hepatocellular carcinoma cells.
|
30030687 |
2019 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Collectively, the results first suggested that lower expression of miR-340 is involved in the development of CDDP resistance in hepatocellular carcinoma cell line, at least partly due to regulating Nrf2-dependent antioxidant pathway.
|
25556489 |
2014 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Collectively, we demonstrated that SLC27A5 acts as a novel tumor suppressor by suppressing TXNRD1 expression via the KEAP1/NRF2 pathway in HCC.
|
31367013 |
2020 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Combination therapy in a TAA-induced HCC rat model was more effective than 5-FU or Vit D through the modulation of TGF-β1, caspase-3, and NrF2 expressions.
|
30205014 |
2018 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Consistently, the HCA/HCC lesions developed in the G6Pase-α-deficient livers display marked accumulation of p62 aggregates and phosphorylated p62 along with activation of Nrf2 and mTORC1 signaling.
|
31735334 |
2020 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Correction: Camptothecin suppresses NRF2-ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs.
|
31350527 |
2019 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Expression of Nrf2 (n = 100) and 8-OHdG (n = 53) was remarkably increased in HCC tissues compared with the noncancerous hepatic tissues.
|
28281193 |
2017 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, HCC cell treatment significantly decreased the expression levels of Nrf2 and its downstream effectors,
|
27213353 |
2016 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Gankyrin has an antioxidative role through the feedback regulation of Nrf2 in hepatocellular carcinoma.
|
27091842 |
2016 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
GSH depletion caused by GSTZ1 deficiency elevates oxidative stress, thus constitutively activating the NRF2 antioxidant response pathway and accelerating HCC progression.
|
31666108 |
2019 |
|
Liver carcinoma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Here, we aimed to investigate the correlation between NRF2, Kelch-like ECH-associated protein 1 (KEAP1) syntheses and p62 phosphorylation in HCC.
|
27246794 |
2016 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we demonstrated that AMPK activator AICAR, in contrary to the A769662 allosteric activator, induces Nrf2 activation and concomitantly modulates the basal redox state of the hepatocarcinoma cells.
|
25058527 |
2014 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Herein, we examined whether Nrf2 (Nfe2l2) activation occurs at early steps of rat hepatocarcinogenesis, to assess critical contributions of Nrf2 to the onset of hepatocellular carcinoma (HCC).
|
29758334 |
2018 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
High p62 expression is needed for activation of NRF2 and mTORC1, induction of c-Myc, and protection of HCC-initiating cells from oxidative stress-induced death.
|
27211490 |
2016 |
|
Liver carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
High-throughput short-read sequencing of exomes and whole cancer genomes in multiple human hepatocellular carcinoma (HCC) cohorts confirmed previously identified frequently mutated somatic genes, such as TP53, CTNNB1 and AXIN1, and identified several novel genes with moderate mutation frequencies, including ARID1A, ARID2, MLL, MLL2, MLL3, MLL4, IRF2, ATM, CDKN2A, FGF19, PIK3CA, RPS6KA3, JAK1, KEAP1, NFE2L2, C16orf62, LEPR, RAC2, and IL6ST.
|
24379610 |
2013 |